Get Our Latest Report on REGENXBIO REGENXBIO Stock Performance REGENXBIO stock opened at $5.94 on Friday. The firm has a market cap of $297.69 million, a price-to-earnings ratio of -1.18 and a ...

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are presently covering the stock, Marketbeat reports.

In an interview over the weekend, FDA Commissioner Dr. Marty Makary came across as “scientifically-grounded level-headed with regards to ...

Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...

Culley, Lineage’s Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharmaceuticals, Inc., and others, as part of ...

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers.

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In ...